Blog / Merck & Company (MRK) Blue-Chip Dividend Growth Stock On Sale

Merck & Company (MRK) Blue-Chip Dividend Growth Stock On Sale

Dividend Growth Stock On Sale

Merck & Company (MRK) is what I consider to be a very high quality blue-chip dividend growth stock that promises both some good current income and growth of future income, as well as capital appreciation.  Most importantly of all, I believe it’s very attractively-valued today. 

In this video I am going look a little deeper into the dividend growth stock pharmaceutical giant.  It’s really a very interesting company to me and there’s some interesting attributes about pharmaceuticals that I think are worth mentioning.

In today’s overheated stock market it is very difficult to find any decent quality dividend growth stock at an attractive valuation. It is even more difficult to find an impeccable blue-chip quality stock on sale.

Merck & Company is an AA- rated blue-chip Dividend Contender that offers a dividend yield in excess of 3% and the opportunity to earn high double-digit annualized rates of return over the next 3 to 5 years and beyond. In this video I take a comprehensive look at the company and its potential going forward.

Dividend Growth Stock Merck

Here are some links to research that are referred to in the video:

Lark Research

Organon Presentation

Merck Earnings

FAST Graphs Analyze Out Loud Reviewing Merck & Company

FAST Graphs Analyze Out Loud Video

Try FAST Graphs for FREE Today!

SUBSCRIBE to our YouTube Channel

Click here for our Research Articles

Disclosure:  No position.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.